Emerging Medication for mCRPC Gets FDA Fast Track Designation for Adjunctive Use with Radiation Therapy
Currently in a phase I trial for solid prostate cancer tumors, the deoxycytidine kinase inhibitor TRE-515 garnered the fast track designation for possible combination use with Pluvicto in treating mCRPC.
The Food and Drug Administration (FDA) has issued a fast track designation for adjunctive use of TRE-515, an oral deoxycytidine kinase inhibitor, with lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Trethera, the developer of TRE-515, said the medication is currently being evaluated as an oral monotherapy in a phase I study for the treatment of advanced prostate cancer (PCa) tumors.
TRE-515, an emerging oral deoxycytidine kinase inhibitor, has been granted a FDA fast track designation for adjunctive use in combination with lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). (Image courtesy of Adobe Stock.)
Preliminary findings from the multicenter dose-escalation study suggest that TRE-515 may offer anti-tumor activity and researchers have also noted an 18-fold escalation of dosing with the agent without any limiting toxicity, according to Trethera.
“I believe that TRE-515 has the potential to make a meaningful difference in the lives of prostate cancer patients and I am pleased that Trethera has received this Fast Track designation to expedite development,” said Michael Jung, Ph.D., a distinguished UCLA professor of chemistry and biochemistry, and inventor of TRE-515. “The chemical structure of TRE-515 was designed for a specific, on-target, binding to create an optimal drug profile.”
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
